19:20 , Apr 27, 2018 |  BC Week In Review  |  Clinical News

ADC Therapeutics discontinues HER2 program

ADC Therapeutics S.A. (Épalinges, Switzerland) said it discontinued ADCT-502 after Phase I data of the antibody-drug conjugate (ADC) in patients with HER2-expressing advanced solid tumors did not show "sufficient patient benefit to justify further development."...
18:51 , Apr 25, 2018 |  BC Extra  |  Clinical News

ADC Therapeutics discontinues HER2 program

ADC Therapeutics S.A. (Épalinges, Switzerland) said it discontinued ADCT-502 after Phase I data of the antibody-drug conjugate (ADC) in patients with HER2-expressing advanced solid tumors did not show "sufficient patient benefit to justify further development."...
19:02 , Oct 27, 2017 |  BC Week In Review  |  Financial News

ADC raises $200M private placement

On Oct. 23, antibody-drug conjugate company ADC Therapeutics S.A. (Épalinges, Switzerland) raised $200 million in a private placement from Auven Therapeutics Management, Redmile, the Wild Family Office and AstraZeneca plc (LSE:AZN; NYSE:AZN). Next year, ADC...
09:25 , Oct 23, 2017 |  BC Extra  |  Financial News

ADC Therapeutics raises $200M

Antibody-drug conjugate company ADC Therapeutics S.A. (Épalinges, Switzerland) raised $200 million in a private placement from Auven Therapeutics Management, Redmile, the Wild Family Office and AstraZeneca plc (LSE:AZN; NYSE:AZN). Next year, ADC Therapeutics plans to...